David H Howard

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4533205/publications.pdf

Version: 2024-02-01

109 papers 3,767 citations

147801 31 h-index 58 g-index

112 all docs

112 docs citations

112 times ranked

5065 citing authors

#	Article	IF	CITATIONS
1	Producing Organ Donors. Journal of Economic Perspectives, 2007, 21, 25-36.	5.9	478
2	The impact of low health literacy on the medical costs of Medicare managed care enrollees. American Journal of Medicine, 2005, 118, 371-377.	1.5	391
3	Pricing in the Market for Anticancer Drugs. Journal of Economic Perspectives, 2015, 29, 139-162.	5.9	379
4	Impact of health literacy on socioeconomic and racial differences in health in an elderly population. Journal of General Internal Medicine, 2006, 21, 857-861.	2.6	257
5	Association Between Combined <i>TMPRSS2:ERG</i> and <i>PCA3</i> RNA Urinary Testing and Detection of Aggressive Prostate Cancer. JAMA Oncology, 2017, 3, 1085.	7.1	120
6	The Global Impact of Drug Resistance. Clinical Infectious Diseases, 2003, 36, S4-S10.	5.8	90
7	Racial/ethnic disparities in waitlisting for deceased donor kidney transplantation 1 year after implementation of the new national kidney allocation system. American Journal of Transplantation, 2018, 18, 1936-1946.	4.7	84
8	New Kidney Allocation System Associated With Increased Rates Of Transplants Among Black And Hispanic Patients. Health Affairs, 2017, 36, 1078-1085.	5.2	79
9	Absenteeism and Employer Costs Associated With Chronic Diseases and Health Risk Factors in the US Workforce. Preventing Chronic Disease, 2016, 13, E141.	3.4	70
10	Measuring the Economic Costs of Antimicrobial Resistance in Hospital Settings: Summary of the Centers for Disease Control and Prevention–Emory Workshop. Clinical Infectious Diseases, 2001, 33, 1573-1578.	5.8	66
11	Does Quality Improvement Work? Evaluation of the Organ Donation Breakthrough Collaborative. Health Services Research, 2007, 42, 2160-2173.	2.0	65
12	Comorbidities, smoking status, and life expectancy among individuals eligible for lung cancer screening. Cancer, 2015, 121, 4341-4347.	4.1	59
13	Why do transplant surgeons turn down organs?. Journal of Health Economics, 2002, 21, 957-969.	2.7	57
14	Mandatory Shared Decision Making by the Centers for Medicare & Medicaid Services for Cardiovascular Procedures and Other Tests. JAMA - Journal of the American Medical Association, 2018, 320, 641.	7.4	56
15	Mammography rates after the 2009 US Preventive Services Task Force breast cancer screening recommendation. Preventive Medicine, 2012, 55, 485-487.	3.4	47
16	Drug Companies' Patient-Assistance Programs â€" Helping Patients or Profits?. New England Journal of Medicine, 2014, 371, 97-99.	27.0	44
17	Cervical cancer screening of underserved women in the United States: results from the National Breast and Cervical Cancer Early Detection Program, 1997–2012. Cancer Causes and Control, 2015, 26, 671-686.	1.8	43
18	Necitumumab in Metastatic Squamous Cell Lung Cancer. JAMA Oncology, 2015, 1, 1293.	7.1	43

#	Article	IF	CITATIONS
19	Adoption of Prebiopsy Magnetic Resonance Imaging for Men Undergoing Prostate Biopsy in the United States. Urology, 2018, 117, 57-63.	1.0	43
20	Breast cancer screening of underserved women in the USA: results from the National Breast and Cervical Cancer Early Detection Program, 1998–2012. Cancer Causes and Control, 2015, 26, 657-668.	1.8	42
21	The Value of New Chemotherapeutic Agents for Metastatic Colorectal Cancer. Archives of Internal Medicine, 2010, 170, 537.	3.8	41
22	The Economic Burden of Drug Resistance. Clinical Infectious Diseases, 2005, 41, S283-S286.	5.8	40
23	Life expectancy and the value of early detection. Journal of Health Economics, 2005, 24, 891-906.	2.7	40
24	Hospital Readmission Is Associated With Poor Survival After Esophagectomy for Esophageal Cancer. Annals of Thoracic Surgery, 2015, 99, 292-297.	1.3	40
25	National estimates of medical costs incurred by nonelderly cancer patients. Cancer, 2004, 100, 883-891.	4.1	37
26	New Anticancer Drugs Associated With Large Increases In Costs And Life Expectancy. Health Affairs, 2016, 35, 1581-1587.	5 . 2	37
27	Do Report Cards Influence Hospital Choice? The Case of Kidney Transplantation. Inquiry (United) Tj ETQq $1\ 1\ 0$.	784314 rgE	BT /Qverlock I
28	Use of Cost-Effectiveness Analysis to Determine Inventory Size for a National Cord Blood Bank. Medical Decision Making, 2008, 28, 243-253.	2.4	36
29	Influenza vaccination rates and beliefs about vaccination among nursing home employees. American Journal of Infection Control, 2015, 43, 100-106.	2.3	36
30	Cost Effectiveness Analysis of Pharmacokinetically-Guided 5-Fluorouracil in FOLFOX Chemotherapy for Metastatic Colorectal Cancer. Clinical Colorectal Cancer, 2014, 13, 219-225.	2.3	35
31	Prostate Cancer Screening In Men Ages 75 And Older Fell By 8 Percentage Points After Task Force Recommendation. Health Affairs, 2013, 32, 596-602.	5.2	34
32	Quality and Consumer Choice in Healthcare: Evidence from Kidney Transplantation. BE Journal of Economic Analysis and Policy, 2006, 5, 1349.	0.3	31
33	Trends in <scp>PCI</scp> Volume after Negative Results from the <scp>COURAGE</scp> Trial. Health Services Research, 2014, 49, 153-170.	2.0	31
34	Should We Promote Organ Donor Registries When So Few Registrants Will End Up Being Donors?. Medical Decision Making, 2007, 27, 243-249.	2.4	29
35	Abandonment of Highâ€Dose Chemotherapy/Hematopoietic Cell Transplants for Breast Cancer Following Negative Trial Results. Health Services Research, 2011, 46, 1762-1777.	2.0	28
36	Declines in Prostate Cancer Incidence After Changes in Screening Recommendations. Archives of Internal Medicine, 2012, 172, 1267.	3.8	28

#	Article	IF	Citations
37	Trends in the Use of Knee Arthroscopy in Adults. JAMA Internal Medicine, 2018, 178, 1557.	5.1	28
38	Resistance-induced antibiotic substitution. Health Economics (United Kingdom), 2004, 13, 585-595.	1.7	26
39	Cancer Screening And Age In The United States And Europe. Health Affairs, 2009, 28, 1838-1847.	5.2	26
40	The impact of a national program to provide free mammograms to lowâ€income, uninsured women on breast cancer mortality rates. Cancer, 2010, 116, 4456-4462.	4.1	25
41	Hospitalization Rates Among Dialysis Patients During Hurricane Katrina. Prehospital and Disaster Medicine, 2012, 27, 325-329.	1.3	25
42	End-of-Life Medical Costs of Medicaid Cancer Patients. Health Services Research, 2015, 50, 690-709.	2.0	25
43	Trends in the use of active surveillance and treatments in Medicare beneficiaries diagnosed with localized prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 432.e1-432.e10.	1.6	23
44	Adverse Effects of Prohibiting Narrow Provider Networks. New England Journal of Medicine, 2014, 371, 591-593.	27.0	22
45	Evidence Of No Benefit From Knee Surgery For Osteoarthritis Led To Coverage Changes And Is Linked To Decline In Procedures. Health Affairs, 2012, 31, 2242-2249.	5.2	20
46	Changes in Geographic Variation in the Use of Percutaneous Coronary Intervention for Stable Ischemic Heart Disease After Publication of the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) Trial. Circulation: Cardiovascular Quality and Outcomes, 2014, 7, 125-130.	2.2	20
47	Psychiatric Practice Patterns and Barriers to the Adoption of Esketamine. JAMA - Journal of the American Medical Association, 2019, 322, 1039.	7.4	20
48	Association of Mandatory-Access Prescription Drug Monitoring Programs With Opioid Prescriptions Among Medicare Patients Treated by a Medical or Hematologic Oncologist. JAMA Oncology, 2020, 6, 1102.	7.1	20
49	Producing Evidence to Reduce Low-Value Care. JAMA Internal Medicine, 2015, 175, 1893.	5.1	18
50	Impact of Negative Clinical Trial Results for Vertebroplasty on Vertebral Augmentation Procedure Rates. Journal of the American College of Surgeons, 2014, 219, 525-533e1.	0.5	17
51	Contrary To Conventional Wisdom, Physicians Abandoned A Breast Cancer Treatment After A Trial Concluded It Was Ineffective. Health Affairs, 2016, 35, 1309-1315.	5.2	17
52	Alternative Payment for Radiation Oncology. JAMA - Journal of the American Medical Association, 2019, 322, 1859.	7.4	17
53	The impact of detection and treatment on lifetime medical costs for patients with precancerous polyps and colorectal cancer. Health Economics (United Kingdom), 2009, 18, 1381-1393.	1.7	16
54	Mammography rates after the 2009 revision to the United States Preventive Services Task Force breast cancer screening recommendation. Cancer Causes and Control, 2017, 28, 41-48.	1.8	16

#	Article	IF	CITATIONS
55	Understanding recent increases in chronic disease treatment rates: more disease or more detection?. Health Economics, Policy and Law, 2010, 5, 411-435.	1.8	14
56	The eligibility and reach of the national breast and cervical cancer early detection program after implementation of the affordable care act. Cancer Causes and Control, 2020, 31, 473-489.	1.8	14
57	THE EFFECT OF CADAVERIC KIDNEY DONATIONS ON LIVING KIDNEY DONATIONS: AN INSTRUMENTAL VARIABLES APPROACH. Economic Inquiry, 2013, 51, 1696-1714.	1.8	13
58	Comparative Effectiveness Research, Technological Abandonment, and Health Care Spending. Advances in Health Economics and Health Services Research, 2012, 23, 103-121.	0.2	12
59	Cost-Savings to Medicare From Pre-Medicare Colorectal Cancer Screening. Medical Care, 2015, 53, 630-638.	2.4	12
60	Sociodemographic disparities in treatment and survival of small localized renal cell carcinoma: surgical resection versus thermal ablation. Journal of Comparative Effectiveness Research, 2016, 5, 441-452.	1.4	12
61	Initial and Follow-up Costs by Treatment Outcome for Children With Respiratory Infections. Pediatrics, 2004, 113, 1352-1356.	2.1	11
62	Hospital Quality and Selective Contracting: Evidence from Kidney Transplantation. Forum for Health Economics and Policy, 2008, 11, 2.	0.8	11
63	SUBSIDIZING ALTRUISM IN LIVING ORGAN DONATION. Economic Inquiry, 2018, 56, 398-423.	1.8	11
64	The accuracy of claims data for measuring transfusion rates. Transfusion Medicine, 2016, 26, 457-459.	1.1	10
65	Relationship Between Adherence to Antihypertensive Medication Regimen and Out-of-Pocket Costs Among People Aged 35 to 64 With Employer-Sponsored Health Insurance. Preventing Chronic Disease, 2019, 16, E32.	3.4	10
66	Physician age and the abandonment of episiotomy. Health Services Research, 2019, 54, 650-657.	2.0	10
67	Selective Hearing: Physicianâ€Ownership and Physicians' Response to New Evidence. Journal of Economics and Management Strategy, 2017, 26, 152-168.	0.8	9
68	Eliminating costâ€sharing requirements for colon cancer screening in <scp>M</scp> edicare. Cancer, 2014, 120, 3850-3852.	4.1	8
69	Sociodemographic impact on survival in unresectable hepatocellular carcinoma: a survival epidemiology and end results study. Future Oncology, 2016, 12, 183-198.	2.4	8
70	Patterns of use and survival outcomes of positron emission tomography for initial staging in elderly follicular lymphoma patients. Leukemia and Lymphoma, 2017, 58, 1570-1580.	1.3	8
71	Intensity-Modulated Radiation Therapy in Breast Cancer Patients Following the Release of a Choosing Wisely Recommendation. Journal of the National Cancer Institute, 2020, 112, 314-317.	6.3	8
72	WAITING TIME AS A PRICE FOR DECEASED DONOR KIDNEYS*. Contemporary Economic Policy, 2011, 29, 295-303.	1.7	7

#	Article	IF	CITATIONS
73	Serious Health Events and Discontinuation of Routine Cancer Screening. Medical Decision Making, 2012, 32, 627-635.	2.4	7
74	Can major systematic reviews influence practice patterns? A case study of episiotomy trends. Archives of Gynecology and Obstetrics, 2013, 288, 1285-1293.	1.7	7
75	The Living Donor Lost Wages Trial: Study Rationale and Protocol. Current Transplantation Reports, 2018, 5, 45-54.	2.0	7
76	Deterrence effects of antifraud and abuse enforcement in health care. Journal of Health Economics, 2021, 75, 102405.	2.7	7
77	Drivers of <scp>US</scp> health care spending for persons with seizures and/or epilepsies, 2010–2018. Epilepsia, 2022, 63, 2144-2154.	5.1	7
78	Variation in Use of Prostate Biopsy Following Changes in Prostate Cancer Screening Guidelines. Journal of Urology, 2017, 198, 1046-1053.	0.4	6
79	Impact of prebiopsy magnetic resonance imaging of the prostate on cancer detection and treatment patterns. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 181.e15-181.e21.	1.6	6
80	US False Claims Act Investigations of Unnecessary Percutaneous Coronary Interventions. JAMA Internal Medicine, 2020, 180, 1534.	5.1	6
81	Disparities in magnetic resonance imaging of the prostate for traditionally underserved patients with prostate cancer. Cancer, 2021, 127, 2974-2979.	4.1	6
82	The value of new drugs for advanced prostate cancer. Cancer, 2021, 127, 3457-3465.	4.1	6
83	The Relationship between Ex Ante Mortality Risk and End-of-Life Medical Costs. Applied Health Economics and Health Policy, 2006, 5, 37-44.	2.1	5
84	False Claims Act Liability for Overtreatment. Journal of Health Politics, Policy and Law, 2020, 45, 419-437.	1.9	5
85	Cancer-directed therapy and potential impact on survivals in nonresected hepatocellular carcinoma: SEER-Medicare population study. Future Oncology, 2017, 13, 2021-2033.	2.4	4
86	Does Bad News Travel Faster? On the Determinants of Medical Technology Abandonment. Journal of Human Capital, 2018, 12, 569-603.	1.3	4
87	Payments and Patient Cost Sharing for Prostate Biopsies According to Image Guidance, Practice Site and Use of Anesthesia. Urology Practice, 2020, 7, 138-144.	0.5	4
88	Nursing homes' preparedness plans and capabilities. American Journal of Disaster Medicine, 2012, 7, 127-135.	0.3	4
89	Realigning Incentives for Developing and Pricing New Anticancer Treatments. JAMA - Journal of the American Medical Association, 2011, 305, 2347.	7.4	3
90	Trends in transfusion rates after the FOCUS trial. Journal of Comparative Effectiveness Research, 2018, 7, 113-120.	1.4	3

#	Article	IF	CITATIONS
91	Cancer Survivorship and Supportive Care Economics Research: Current Challenges and Next Steps. Journal of the National Cancer Institute Monographs, 2022, 2022, 57-63.	2.1	3
92	Hospital and skilled nursing facility patient flows during Hurricane Katrina and the Midwest floods of 2008. Health Systems, 2015, 4, 29-40.	1.2	2
93	Capsule Commentary on Mehta et al. Race/Ethnicity and Adoption of a Population Health Management Approach to Colorectal Cancer Screening in a Community-Based Healthcare System. Journal of General Internal Medicine, 2016, 31, 1356-1356.	2.6	2
94	Association Between Self-Reported Hypertension and Antihypertensive Medication Use and Cardiovascular Disease–Related Events and Expenditures Among Patients Diagnosed With Hypertension. Public Health Reports, 2019, 134, 493-501.	2.5	2
95	Medicare fee reductions and the overuse of intensityâ€modulated radiotherapy. Health Services Research, 2021, 56, 626-634.	2.0	2
96	The Living Donor Lost Wages Trial: Study Rationale and Protocol. Current Transplantation Reports, 2018, 5, 45-54.	2.0	2
97	Physician Reimbursement for Prostate Biopsies Falls as Procedures Shift From Offices to Facilities. Urology, 2018, 115, 96-101.	1.0	1
98	Implementation of Florida Long Term Care Emergency Preparedness Portal Web Site, 2015–2017. American Journal of Public Health, 2018, 108, S399-S401.	2.7	1
99	Cost-effectiveness analysis of regorafenib for metastatic colorectal cancer Journal of Clinical Oncology, 2015, 33, 658-658.	1.6	1
100	Provider-owned insurers in the individual market. American Journal of Managed Care, 2018, 24, e393-e398.	1.1	1
101	Rising Medicare Costs: The Authors Respond. Health Affairs, 2006, 25, W391-W392.	5.2	0
102	Just Health: Meeting Health Needs Fairly. JAMA - Journal of the American Medical Association, 2008, 299, 2568.	7.4	0
103	Comparative Effectiveness Research and Cancer Screening in the United States and Europe. Medical Decision Making, 2009, 29, NP12-NP13.	2.4	0
104	Perspectives in Oncology Drug Pricing—Reply. JAMA Oncology, 2016, 2, 402.	7.1	0
105	Radiation Oncology Alternative Payment Model—Reply. JAMA - Journal of the American Medical Association, 2020, 323, 999.	7.4	0
106	Impact of Medicaid reimbursement and eligibility policies on receipt of cancer screening Journal of Clinical Oncology, 2013, 31, 6514-6514.	1.6	0
107	Cancer Treatment for Dual Eligibles: What Are the Costs and Who Pays?. American Journal of Cancer Science, 2013, 2, 2013010007.	0.0	0
108	Provider-owned insurers. American Journal of Managed Care, 2017, 23, 566-567.	1.1	0

#	Article	lF	CITATIONS
109	Inaccurate Comparison of the COVID-19 Response in the United States and Cuba. American Journal of Public Health, 2022, 112, e4-e4.	2.7	O